Intas Biopharmaceuticals joins hands with Progenetics

RELATED NEWS Dabur Pharma touches 52-week high Dabur Pharma introduces Nanoxel in India Aurobindo receives 2 more USFDA approvals Aventis Pharma Q3 net seen at Rs 43.3cr: ICICI Sec Zandu Pharma to invest Rs 25 cr for Uttaranchal plant Nifty BSE | NSE 28/05/12 Are Mutual Funds betting on Nifty?

Dr. Urmish Chudgar, Managing Director, Intas Biopharmaceuticals said, "Products like Factor IX with a very limited market potential are often neglected by pharma companies. It is estimated that over 5000 patients in India do not have any drug to cure Hemophilia B. We hope to bring relief through our joint commitment by working together towards drug development and treatment for patients suffering from Hemophilia B."

 

Dr. Julian Cooper, CEO of Progenetics, LLC said, "We are pleased to enter into this alliance with Intas Biopharmaceuticals as we believe the synergy will help our companies expand our key strengths and also provide the best medical cure to the patients in India and world over."

 

IBPL is aiming to be a global supplier for transgenic animal platform based products and the company plans to utilize the same transgenic platform for expression of other recombinant proteins in milk to fulfill the objective of the National Hemophilia Foundation & the World Federation of Hemophilia.

 

Sourced From :Imprimis Life PR